Phase 1 study to determine the metabolism and clearance of baxdrostat

Trial Identifier:	CIN-107-117
Sponsor:	AstraZeneca
NCTID::	NCT05961384
Start Date:	November 2021
Primary Completion Date:	January 2022
Study Completion Date:	January 2022
Condition:	Hypertension

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

No documents have been posted yet.

Stay informed about new Trial Results Summaries with our email notification service

Trial Locations

Country	Location
United States, Wisconsin	Madison, Wisconsin, United States, 53704

Pharma Intelligence UK Limited is a company registered in England and Wales with company number 13787459 whose registered office is 3 More London Riverside, London SE1 2AQ.